Pharma-Bio Serv Q3 revenue up ~$0.4M YoY; net loss narrows to $14K

Pharma-Bio Serv, Inc.

2026-Q3 EPS reported $0.01 revenue$7,333,964

Q3 (ended July 31, 2026) revenue ~$2.3M, up ~$0.4M YoY; nine-month revenue ~$7.3M, up ~$0.5M YoY.
Q3 net loss of $14K, an ~$190K improvement YoY; nine-month net income ~$252K, up ~$352K YoY.
CEO Victor Sanchez credits client relationships and specialized compliance capabilities for improved performance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.